Samarium-153-EDTMP bone uptake rate and its relation to therapeutic effect

Area of Science:

• Nuclear Medicine
• Radiopharmacology
• Oncology

Background:

• Bone metastases cause significant pain and morbidity in cancer patients.
• Samarium-153 ethylenediaminetetramethylene phosphonic acid ((153)Sm-EDTMP) is a radiopharmaceutical used for palliative pain relief.
• Accurate assessment of radiopharmaceutical uptake is crucial for optimizing therapeutic outcomes.

Purpose of the Study:

• To evaluate the measurement of (153)Sm-EDTMP bone uptake rate using whole-body scintigraphy.
• To analyze the relationship between the bone uptake rate and the therapeutic effect in patients with painful bone metastases.

Main Methods:

• Sixty-six patients with various carcinomas and bone metastases underwent whole-body scintigraphy 10 minutes and 5 hours post-(153)Sm-EDTMP administration.
• Bone uptake rate was calculated based on scintigraphic data.
• Therapeutic effect was categorized into Complete Response (CR), Partial Response (PR), and Non-Response (NR) based on metastasis changes, Karnofsky Performance Score (KPS), and pain remission.

Main Results:

• The bone uptake rate ranged from 31.9% to 86.6% (mean 56.0%).
• The CR group showed the highest mean bone uptake rate (68.7%), followed by the PR group (58.3%), and the NR group (41.0%).
• Significant differences in bone uptake rates were observed between CR and PR groups (P=0.001) and between PR and NR groups (P=0.001).

Conclusions:

• Whole-body scintigraphy provides a reliable method for calculating (153)Sm-EDTMP bone uptake rate.
• A significant correlation exists between (153)Sm-EDTMP bone uptake rate and therapeutic efficacy in palliating bone cancer pain.
• This technique enables personalized dosimetry for (153)Sm-EDTMP to maximize therapeutic benefit while minimizing myelotoxicity.